Latest News

Add to Favorites Subscribe Share
newswise-fb-share-

Showing results

110 of 504
dana-farber-logo.jpg

Article ID: 714005

Walking Speed Points to Future Clinical Outcomes for Older Patients with Blood Cancers

Dana-Farber Cancer Institute

Researchers at Dana-Farber Cancer Institute and the VA Boston Healthcare System have uncovered a new vital sign for gauging survival and likelihood of having an unplanned hospitalization in older patients with blood cancers: the speed at which they can walk.In a study published today in the journal Blood, the researchers report that for every 0.

Released:
5-Jun-2019 4:50 PM EDT
Open in New Tab
Comment
  • Embargo expired:
    2-Jun-2019 7:30 AM EDT

Article ID: 713589

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer

Dana-Farber Cancer Institute

Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC), according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology, during the American Society of Clinical Oncology (ASCO) Annual Meeting.

Released:
2-Jun-2019 6:30 AM EDT
Open in New Tab
Comment
Newswise: Pre-surgical immunotherapy shows promise in trial for patients with early stage lung cancer
  • Embargo expired:
    31-May-2019 9:00 AM EDT

Article ID: 713691

Pre-surgical immunotherapy shows promise in trial for patients with early stage lung cancer

Dana-Farber Cancer Institute

Pre-surgical immunotherapy shows promise in trial for patients with early stage lung cancer

Released:
30-May-2019 2:05 PM EDT
Open in New Tab
Comment
Newswise: Patterns of chronic lymphocytic leukemia growth identified
  • Embargo expired:
    29-May-2019 1:00 PM EDT

Article ID: 713607

Patterns of chronic lymphocytic leukemia growth identified

Dana-Farber Cancer Institute

In patients with chronic lymphocytic leukemia, the rate of disease growth is apt to follow one of three trajectories: relentlessly upward, steadily level, or something in between, scientists at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, Massachusetts General Hospital, and the University of Washington report in a new study.

Released:
29-May-2019 12:00 PM EDT
Open in New Tab
Comment
  • Embargo expired:
    22-May-2019 5:00 PM EDT

Article ID: 713252

Black Men Less Likely Than Nonblack Patients to Adopt Active Surveillance for Low-Risk Prostate Cancer

Dana-Farber Cancer Institute

At a time when a growing number of men with prostate cancer considered “low risk” are opting for active surveillance or watchful waiting rather than immediate treatment with surgery or radiation, a new study reveals that black men are less likely than white men to adopt an active surveillance strategy for their disease.

Released:
21-May-2019 1:05 PM EDT
Open in New Tab
Comment
Newswise: Dana-Farber researchers present findings in more than 70 research studies at ASCO annual meeting 2019

Article ID: 713044

Dana-Farber researchers present findings in more than 70 research studies at ASCO annual meeting 2019

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute researchers are presenting more than 70 research studies at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31st- June 4th. ASCO is the world’s largest clinical cancer research meeting, attracting more than 30,000 oncology professionals from around the world.

Released:
16-May-2019 3:05 PM EDT
Open in New Tab
Comment
dana-farber-logo.jpg
  • Embargo expired:
    24-Apr-2019 5:00 PM EDT

Article ID: 711770

Targeted therapy proves effective against aggressive rare blood cancer

Dana-Farber Cancer Institute

Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease

Released:
23-Apr-2019 11:05 AM EDT
Open in New Tab
Comment
Newswise: Researchers devise a progression risk-based classification for patients with asymptomatic Waldenström macroglobulinemia

Article ID: 711779

Researchers devise a progression risk-based classification for patients with asymptomatic Waldenström macroglobulinemia

Dana-Farber Cancer Institute

Researchers at Dana-Farber Cancer Institute have devised a risk model for determining whether patients with AWM have a low, intermediate, or high risk of developing symptomatic Waldenström macroglobulinemia

Released:
23-Apr-2019 12:05 PM EDT
Open in New Tab
Comment
  • Embargo expired:
    9-Apr-2019 11:00 AM EDT

Article ID: 710911

High-dose vitamin D shows benefit in patients with advanced colorectal cancer

Dana-Farber Cancer Institute

Results of a small clinical trial suggest that supplementing chemotherapy with high doses of vitamin D may benefit patients with metastatic colorectal cancer by delaying progression of the disease, say scientists from Dana-Farber Cancer Institute.

Released:
8-Apr-2019 12:05 PM EDT
Open in New Tab
Comment
dana-farber-logo.jpg

Article ID: 710308

T-Mobile CEO John Legere delivers $4.5 million gift to Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

T-Mobile CEO is giving $4.5 million to support the Profile initiative at Dana-Farber Cancer Institute, one of the broadest and most comprehensive enterprise-level, patient-based cancer genomics projects in the world.

Released:
27-Mar-2019 1:30 PM EDT
Open in New Tab
Comment

Channels:

Cancer


Showing results

110 of 504

Chat now!